1. Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen–Negative Patients With Chronic Hepatitis 
Faisal M. Sanai, Mohammed A. Babatin, Khalid I. Bzeizi, Fahad AlSohaibani, Waleed Al–Hamoudi, Khaled O. Alsaad, Hadeel Al Mana, Fayaz A. Handoo, Hamad Al–Ashgar, Hamdan AlGhamdi, Abeer Ibrahim, Abdulrahman Aljumah, Abduljaleel Alalwan, Ibrahim H. AlTraif, Hussa Al–Hussaini, Robert P. Myers, Ayman A. Abdo 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 11, Pages e2 (November 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Study algorithm showing application of AASLD, USPA, EASL, and APASL guidelines' thresholds of serum HBV DNA and ALT levels.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
ROC curves of the 4 guidelines' criteria for identifying fibrosis ≥F2. In patients meeting AASLD criteria, sensitivity is 56.5% and specificity is 73.8% (AUROC, 0.59; 95% CI, 0.54–0.64); for USPA criteria, sensitivity is 45.7% and specificity is 82.4% (AUROC, 0.66; 95% CI, 0.58–0.73); for EASL criteria, sensitivity is 45.6% and specificity is 82.1% (AUROC, 0.66; 95% CI, 0.61–0.71); and for APASL criteria, sensitivity is 56.3% and specificity is 77.1% (AUROC, 0.64; 95% CI, 0.59–0.69).
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

4. Supplementary Figure 1
Presence of significant histology when HBeAg-negative patients were stratified on basis of the 4 guidelines' criteria. No significant differences were seen in relation to steatosis, ≥A2 necroinflammation, and ≥F2 fibrosis (P > .05 for all).
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

5. Supplementary Figure 2
ROC curve of the best compromise sensitivity-specificity of ALT (>1.09 × ULN) and HBV DNA (>3.91 log10 IU/mL) levels for identifying fibrosis score ≥F2. In patients meeting these criteria, sensitivity is 54.3% and specificity is 81.2% (AUROC, 0.73; 95% CI, 0.68–0.77; P < .0001).
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions